Harry Erba, MD
Medical Oncology · Ann Arbor, MINPI 1508942566
Payments from drug & device makers
Across 1,098 payments — averaging $3769.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$852K
- Sumitomo Pharma America, Inc.$594K
- Incyte Corporation$396K
- Novartis$366K
- Servier Pharmaceuticals LLC$363K
- Daiichi Sankyo Inc.$345K
- plus $1.2M from 27 others
Across 9 payments — averaging $20,837 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$182K
- Bristol Myers Squibb$5K
- Astellas Pharma Global Development$290
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 100 | $852,210 |
| Sumitomo Pharma America, Inc. | 57 | $593,819 |
| Incyte Corporation | 303 | $395,779 |
| Novartis | 63 | $365,714 |
| Servier Pharmaceuticals LLC | 95 | $363,465 |
| Daiichi Sankyo Inc. | 118 | $344,668 |
| AbbVie | 67 | $292,037 |
| Agios Pharmaceuticals, Inc. | 100 | $194,689 |
| Macrogenics, Inc. | 33 | $166,909 |
| Bristol Myers Squibb | 56 | $99,447 |
| Institut DE Recherches Servier | 2 | $97,216 |
| Servier Bioinnovation | 12 | $62,120 |
| Amgen | 15 | $37,002 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $36,146 |
| Otsuka Pharmaceutical Co., Ltd. | 3 | $32,392 |
| Taiho Oncology, Inc. | 9 | $32,312 |
| Gilead(2 entities) | 5 | $27,500 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27,002 |
| PTC Therapeutics, Inc. | 1 | $25,515 |
| Pfizer | 10 | $24,863 |
| Syndax Pharmaceuticals, Inc. | 15 | $20,769 |
| Astellas Pharma US Inc | 5 | $15,374 |
| Genentech USA, Inc. | 3 | $9,942 |
| Immunogen, Inc. | 1 | $7,158 |
| Rigel Pharmaceuticals, Inc. | 4 | $3,938 |
| Daiichi Sankyo Europe GmbH | 1 | $3,257 |
| Genentech, Inc. | 2 | $2,346 |
| Janssen Global Services, LLC | 3 | $2,112 |
| Novo Nordisk | 1 | $1,690 |
| AstraZeneca | 1 | $1,028 |
| Seagen Inc. | 1 | $120 |
| Merck | 1 | $96 |
| Stemline Therapeutics Inc. | 1 | $53 |
How this compares
$4,138,687 in reported general payments places this provider in the 90th percentile of 170 medical oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Ann Arbor
- Moshe TalpazAnn Arbor$13.7M
- Zachery ReichertAnn Arbor$10.6M
- Paul SwiecickiAnn Arbor$7.6M
- Rashmi ChughAnn Arbor$7M
- John KraussAnn Arbor$6.2M
- Vaibhav SahaiAnn Arbor$5.4M
- Francis WordenAnn Arbor$4.2M
- Angel QinAnn Arbor$3.3M
- Maha HussainAnn Arbor$3M
- Gregory KalemkerianAnn Arbor$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.